Quince Stock Price, News & Analysis

Echo Lake Capital has proposed to acquire Quince Therapeutics (NASDAQ:QNCX) for $1.60 per share in cash, representing a 90% premium over the stock's closing price. The offer is compelling, considering Quince currently holds approximately $2.55 per share in cash and investments, with additional assets including potential milestone payments and federal net operating loss carryforwards. Notably, Quince is not actively developing or marketing any drugs, leading to concerns over its valuation and risk of delisting due to a 70% decline in stock price since its recent acquisition.

Quince Therapeutics, Inc. (NASDAQ: QNCX) has announced an update on its development pipeline and business strategy for 2023. The company aims to prioritize resources on acquiring clinical-stage assets targeting rare diseases and intends to out-license its bone-targeting drug platform and NOV004, an anabolic peptide for accelerated fracture repair. Quince holds approximately $94 million in cash, with a projected annual expenditure of around $11 million in 2023, ensuring a runway until at least 2028. The company is actively seeking partnerships to enhance its strategic growth and has completed all IND-enabling studies for NOV004, preparing for out-licensing by the end of 2023.

Quince Therapeutics (QNCX) has announced the sale of its legacy small molecule protease inhibitor portfolio to Lighthouse Pharmaceuticals. This portfolio includes compounds such as COR588, which targets Alzheimer's disease. Quince aims to offload these assets for strategic focus and operational efficiency. The deal could yield Quince up to $150 million in milestone payments, along with tiered royalties on sales. They will also receive a 7.5% ownership stake in Lighthouse. Additionally, Quince anticipates an annual expense reduction exceeding $500,000 linked to these assets.

Quince Therapeutics, Inc. (QNCX) showcased its innovative bone-targeting platform at the Military Health System Research Symposium 2022. The company's lead compound, NOV004, exhibited potential to accelerate healing in traumatic bone injuries, reducing healing time by 50% in animal models. Quince's approach targets bone fractures directly, offering a unique solution in a market lacking FDA-approved systemic therapies for fracture repair. The company plans to advance NOV004 into Phase 1 clinical studies in 2023, focusing on osteogenesis imperfecta and other significant bone diseases.

Quince Therapeutics (NASDAQ: QNCX) presented at the ASBMR 2022, highlighting its innovative bone-targeting platform for treating spinal fusion and bone cancer. The company showcased two preclinical studies: one on NOV004, aimed at improving spinal fusion outcomes through targeted delivery, and another focusing on a radioactive conjugate for bone cancer therapy. Both approaches aim to enhance healing and patient outcomes by directly addressing bone injuries and diseases.

Quince Therapeutics (NASDAQ: QNCX) presented promising preclinical data at the 14th International Conference on Osteogenesis Imperfecta (OI 2022) regarding its novel therapeutic NOV004. The data indicates NOV004's potential to significantly enhance bone density, strength, and healing in osteogenesis imperfecta (OI). In preclinical models, a two-fold improvement in calcified bone and a three-fold increase in maximum load were documented. NOV004 is slated to enter Phase 1 clinical studies in 2023, aiming to address unmet medical needs in OI.

Quince Therapeutics, Inc. (QNCX) has announced its participation in key scientific meetings in September 2022, including the 14th International Conference on Osteogenesis Imperfecta, ASBMR 2022, and the Military Health System Research Symposium. Key presentations will focus on their novel therapies for bone diseases, including Fracture-targeted Anabolics and Improved Spinal Fusion. The company's lead candidate, NOV004, is engineered for targeted delivery to enhance bone healing and is expected to enter Phase 1 clinical studies in 2023.

Quince Therapeutics, Inc. (NASDAQ: QNCX) announced that CEO Dirk Thye will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 9:00 a.m. ET. Investors can access a live webcast on the Investor Calendar page of Quince's website. The company focuses on innovative precision therapeutics for rare diseases, with its lead compound, NOV004, aimed at treating osteogenesis imperfecta and promoting rapid bone healing. NOV004 is set to enter Phase 1 clinical trials in 2023, targeting major unmet medical needs in bone health.

Quince Therapeutics, trading under the new Nasdaq ticker symbol QNCX, announces a strategic focus on developing precision therapeutics for rare diseases. The company emphasizes its lead molecule, NOV004, a bone-targeting drug designed to address significant unmet medical needs, particularly in skeletal indications. With approximately $105 million in cash, Quince expects to fund operations into the second half of 2025. The strategic plan includes acquiring clinical-stage assets and out-licensing legacy products, enhancing its pipeline in underserved therapeutic areas.